



EXPEDITE DRUG DISCOVERY + CLONE SELECTION WITH THE PROTEOMETER-L KIT

Novilytic's Proteometer™ ("Proteoform Meter") is the world's first nanotechnology for at-line molecular structure analysis from crude culture filtrate.

It performs batch analysis in less than 10 minutes and eliminates the need for sample preparation, Protein A purification, and mass spectrometry. It works by simply plugging the Proteometer into any HPLC with a fluorescence detector.



A NEW BREAKTHROUGH IN DRUG DISCOVERY AND CLONE SELECTION CAN NOW TRIM THE CURRENT 5-10 DAYS OF ANALYTICAL TESTING INTO A SINGLE DAY.

The product expedites the time required to potentially run over 1,000 samples/tests into one day.¹


This represents a total cost savings of \$800K - \$1.8M per clone selection DoE based on \$200K^{2,3,4} per day cost for drug development (4-9 workdays saved multiplied by \$200K per day).

COMPONENTS OF THE PROTEOMETER-L KIT

The kit comes with a reactor, buffer, reagents, and instructions. It is extremely easy to use and does not require a highly trained specialist to operate.

VIDEOS

#1: See how simple the product is to use with our demonstration video.




#2: Listen to a customer at a major pharmaceutical company share how our technology could enable him to complete a projected > 1,000 tests per day.



"We use the Proteometer-L Kit for the rapid analysis of mAbs for titer and aggregate content from cell-free filtrate samples. It eliminates sample preparation steps, protein A purification, and mass spectrometric analysis. I would recommend the Proteometer-L to any pharmaceutical company to quickly and accurately quantitate mAb titer and aggregate content."

Harsha Gunawardena, Ph.D., Principal Scientist, Janssen Pharmaceuticals (Johnson & Johnson's research division)



Email info@novilytic.com to receive your formal quotation today.

¹"Analytical Innovations to Speed-Up Antibody Characterization" Harsha Gunawardena, Ph.D. Principal Scientist, Janssen R&D (Johnson & Johnson), ASMS Breakfast 05 July 2023 (Sponsored by Agilent Technologies)

²Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA, 323(9), 844. <https://doi.org/10.1001/jama.2020.1166>

³Vieira, M. (2020, January). Costs of Pharmaceutical R&D. Knowledge Portal. <https://www.knowledgeportal.org/costs-r-d>

⁴JAMA, March 3, 2020; Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018; Olivier J. Wouters, PhD1; Martin McKee, MD, DSc2; Jeroen Luyten, PhD3; Average cost range, 10 year development